Research programme: DNA interference therapies - Sierra OncologyAlternative Names: PNT 100; PNT 200; PNT 300; PNT 400; PNT 500; PNT 600
Latest Information Update: 11 Jan 2017
At a glance
- Originator ProNAi Therapeutics
- Developer Sierra Oncology
- Class Oligonucleotides
- Mechanism of Action BIRC5 protein modulators; DNA modulators; KRAS protein modulators; Proto-oncogene protein c-bcl-2 modulators; STAT3 transcription factor modulators; Transforming growth factor alpha modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer